MedPath

Delirium treatment at the geriatric ward (DELTa G)Treatment of delirium: rivastigmine or haloperidol as primary treatment for delirium in delirious patients on a geriatric ward.A randomized placebo-controlled study.

Recruiting
Conditions
radndomized placebo-controlled study on a geriatric ward.
Registration Number
NL-OMON29295
Lead Sponsor
trial medication is sponsored by Novartis
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
100
Inclusion Criteria

Patients on a geriatric ward and delirium.

Exclusion Criteria

1. Already use of rivastigmine/donepezil or galantamine;

2. Parkinson(ism).

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ength of delirium.
Secondary Outcome Measures
NameTimeMethod
1. Length of stay in hospital;<br /><br>2. Severity of delirium;<br /><br>3. Need of escape medication;<br /><br>4. Functional status, 3, 6 and 13 weeks after delirium;<br /><br>5. Cognition.
© Copyright 2025. All Rights Reserved by MedPath